The Europe Biosimulation Market is expected to witness market growth of 16.3% CAGR during the forecast period (2024-2031).
The Germany market dominated the Europe Biosimulation Market by country in 2023, and is expected to continue to be a dominant market till 2031; thereby, achieving a market value of $644.3 million by 2031. The UK market is exhibiting a CAGR of 15.3% during 2024-2031. Additionally, the France market is expected to experience a CAGR of 17.1% during 2024-2031.
One of the primary drivers of this market is the rapid advancement in computational power and technologies such as artificial intelligence (AI) and machine learning (ML). These technologies have enhanced the accuracy and scalability of these models, enabling researchers to simulate complex biological interactions that were previously beyond reach.
Initiatives such as the FDA’s Model-Informed Drug Development (MIDD) program have encouraged the adoption of this for regulatory submissions, allowing pharmaceutical companies to expedite approvals and bring innovative therapies to market faster. This regulatory endorsement has also led to integrating this into clinical trial designs, helping researchers identify optimal patient cohorts and minimize risks.
Switzerland and Italy further contribute to the European market, focusing on biotechnology and healthcare digitization. In Switzerland, companies like Novartis and Roche have employed this for cardiovascular drugs and Alzheimer’s treatments, supported by funding from the Swiss Innovation Agency (Innosuisse). Under the National Recovery and Resilience Plan (NRRP), Italy has promoted this for respiratory disorder therapies, with companies like Chiesi Group and academic institutions exploring its potential in rare disease research. These efforts highlight Europe’s collaborative and innovative landscape, where they drives advancements across diverse therapeutic areas.
The Germany market dominated the Europe Biosimulation Market by country in 2023, and is expected to continue to be a dominant market till 2031; thereby, achieving a market value of $644.3 million by 2031. The UK market is exhibiting a CAGR of 15.3% during 2024-2031. Additionally, the France market is expected to experience a CAGR of 17.1% during 2024-2031.
One of the primary drivers of this market is the rapid advancement in computational power and technologies such as artificial intelligence (AI) and machine learning (ML). These technologies have enhanced the accuracy and scalability of these models, enabling researchers to simulate complex biological interactions that were previously beyond reach.
Initiatives such as the FDA’s Model-Informed Drug Development (MIDD) program have encouraged the adoption of this for regulatory submissions, allowing pharmaceutical companies to expedite approvals and bring innovative therapies to market faster. This regulatory endorsement has also led to integrating this into clinical trial designs, helping researchers identify optimal patient cohorts and minimize risks.
Switzerland and Italy further contribute to the European market, focusing on biotechnology and healthcare digitization. In Switzerland, companies like Novartis and Roche have employed this for cardiovascular drugs and Alzheimer’s treatments, supported by funding from the Swiss Innovation Agency (Innosuisse). Under the National Recovery and Resilience Plan (NRRP), Italy has promoted this for respiratory disorder therapies, with companies like Chiesi Group and academic institutions exploring its potential in rare disease research. These efforts highlight Europe’s collaborative and innovative landscape, where they drives advancements across diverse therapeutic areas.
List of Key Companies Profiled
- Certara, Inc.
- Dassault Systemes SE
- Advanced Chemistry Development, Inc.
- Genedata AG (Danaher Corporation)
- Instem Group of Companies
- Chemical Computing Group ULC
- Simulations Plus, Inc.
- Schrodinger, Inc.
- PPD, Inc. (Thermo Fisher Scientific, Inc.)
- Physiomics Plc
Market Report Segmentation
By Product- Software
- Molecular Modeling & Simulation Software
- Clinical Trial Design Software
- PK/PD Modeling and Simulation Software
- Pbpk Modeling and Simulation Software
- Toxicity Prediction Software
- Other Software Type
- Services
- Contract Services
- Consulting
- Other Services Type
- License-based Model
- Subscription-based Model
- Service-based Model
- Pay Per Use Model
- Life Sciences Companies
- Academic Research Institutions
- Other End Use
- Drug Discovery & Development
- Disease Modeling
- Other Application
- Cloud-based
- On-premises
- Hybrid Model
- Oncology
- Cardiovascular Disease
- Infectious Disease
- Neurological Disorders
- Other Therapeutic Area
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. Europe Biosimulation Market by Product
Chapter 6. Europe Biosimulation Market by Pricing Model
Chapter 7. Europe Biosimulation Market by End Use
Chapter 8. Europe Biosimulation Market by Application
Chapter 9. Europe Biosimulation Market by Deployment Model
Chapter 10. Europe Biosimulation Market by Therapeutic Area
Chapter 11. Europe Biosimulation Market by Country
Chapter 12. Company Profiles
Companies Mentioned
- Certara, Inc.
- Dassault Systemes SE
- Advanced Chemistry Development, Inc.
- Genedata AG (Danaher Corporation)
- Instem Group of Companies
- Chemical Computing Group ULC
- Simulations Plus, Inc.
- Schrodinger, Inc.
- PPD, Inc. (Thermo Fisher Scientific, Inc.)
- Physiomics Plc
Methodology
LOADING...
